---
title: "Linzess (linaclotide), all indications: Pharmacology questions"
description: "Pharmacology questions on Linzess (linaclotide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Linzess work (mechanism of action)? Is Linzess a laxative? What is the half-life of Linzess? How is Linzess metabolized and eliminated? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/linzess/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Linzess (linaclotide), all indications: Pharmacology questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)  
Indication pages: [Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)

## Mechanism

<a id="linzess-mechanism"></a>

### How does Linzess work (mechanism of action)?

> “Linaclotide is structurally related to human guanylin and uroguanylin and functions as a 
> guanylate cyclase-C (GC-C) agonist. Both linaclotide and its active metabolite bind to GC-C 
> and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in 
> an increase in both intracellular and extracellular concentrations of cyclic guanosine 
> monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and 
> bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis 
> transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal 
> fluid and accelerated transit. In animal models, linaclotide has been shown to both accelerate 
> GI transit and reduce intestinal pain.  
>
> In an animal model of visceral pain, linaclotide reduced abdominal muscle contraction and 
> decreased the activity of pain-sensing nerves by increasing extracellular cGMP.”

Source: [LINZESS: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=12)

> “LINZESS acts locally within the GI tract and has negligible systemic availability<sup>1</sup>”

Source: [LINZESS: Mechanism of Action in IBS-C, captured 2026-11-14](https://www.linzesshcp.com/ibs-c-moa#:~:text=LINZESS%20acts%20locally%20within%20the%20GI%20tract%20and%20has%20negligible%20systemic)

> “<sup>†</sup>The clinical relevance of the effect on nerve fibers has not been established.<sup>1</sup>”

Source: [LINZESS: Mechanism of Action in IBS-C, captured 2026-11-14](https://www.linzesshcp.com/ibs-c-moa#:~:text=clinical%20relevance%20of%20the%20effect%20on%20nerve%20fibers%20has%20not%20been)

<a id="linzess-laxative"></a>

### Is Linzess a laxative?

> “LINZESS is not a laxative and works differently<sup>1,2</sup>”

Source: [LINZESS: Mechanism of Action in IBS-C, captured 2026-11-14](https://www.linzesshcp.com/ibs-c-moa#:~:text=LINZESS%20is%20not%20a%20laxative%20and%20works)

> “LINZESS (linaclotide) is a guanylate cyclase-C (GC-C) agonist.”

Source: [LINZESS: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=12)

Note: The first statement is the manufacturer's, from its IBS-C mechanism of action page. The Prescribing Information describes linaclotide as a guanylate cyclase-C (GC-C) agonist; its mechanism of action is quoted under the mechanism of action question.

## Pharmacokinetics

<a id="linzess-half-life"></a>

### What is the half-life of Linzess?

> “LINZESS is minimally absorbed with negligible systemic availability following oral 
> administration. Concentrations of linaclotide and its active metabolite in plasma are below the 
> limit of quantitation after oral doses of 72 mcg, 145 mcg, or 290 mcg were administered. 
> Therefore, standard pharmacokinetic parameters such as area under the curve (AUC), 
> maximum concentration (Cmax), and half-life (t½) cannot be calculated.”

Source: [LINZESS: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=13)

> “Given that linaclotide plasma concentrations following recommended oral doses are not 
> measurable, linaclotide is not expected to be distributed to tissues to any clinically relevant 
> extent.”

Source: [LINZESS: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=13)

<a id="linzess-metabolism"></a>

### How is Linzess metabolized and eliminated?

> “Linaclotide is metabolized within the gastrointestinal tract to its principal, active metabolite 
> by loss of the terminal tyrosine moiety. Both linaclotide and the metabolite are 
> proteolytically degraded within the intestinal lumen to smaller peptides and naturally 
> occurring amino acids.”

Source: [LINZESS: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=13)

> “Active peptide recovery in the stool samples of fed and fasted healthy subjects following 
> administration of LINZESS 290 mcg once daily for seven days averaged about 5% (fasted) 
> and about 3% (fed) and all of it as the active metabolite.”

Source: [LINZESS: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=13)

## Components

<a id="linzess-inactive-ingredients"></a>

### What are the inactive ingredients in Linzess?

> “Linaclotide is an amorphous, white to off-white powder. It is slightly soluble in water and 
> aqueous sodium chloride (0.9%). LINZESS contains linaclotide-coated beads in hard gelatin 
> capsules. LINZESS is available as 72 mcg, 145 mcg and 290 mcg capsules for oral 
> administration.”

Source: [LINZESS: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=12)

> “The inactive ingredients of LINZESS 72 mcg capsules include: calcium chloride dihydrate, L-
> histidine, microcrystalline cellulose, polyvinyl alcohol, and talc. The components of the capsule 
> shell include gelatin and titanium dioxide.”

Source: [LINZESS: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=12)

> “The inactive ingredients of LINZESS 145 mcg and 290 mcg capsules include: calcium chloride 
> dihydrate, hypromellose, L-leucine, and microcrystalline cellulose. The components of the 
> capsule shell include gelatin and titanium dioxide.”

Source: [LINZESS: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=12)

## Related pages
- [Medical information: Linzess (linaclotide): All indications](https://www.evicenter.com/medical-information/linzess)
- [Indication](https://www.evicenter.com/medical-information/linzess/indication)
- [Safety](https://www.evicenter.com/medical-information/linzess/safety)
- [Specific populations](https://www.evicenter.com/medical-information/linzess/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/linzess/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/linzess/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/linzess/access-and-coverage)
